Evidence map›Paper›PMID 35690369›Full record

ArticleThe journal of allergy and clinical immunology. In practice2022

Retrospective stratification of cephalosporin allergy label risk using validated penicillin allergy frameworks.

Grace Koo, Roger Yu, Elizabeth J Phillips, Cosby A Stone

Abstract read
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Direct challenges are safe and effective in children with low-risk allergies to oral cephalosporins.The journal of allergy and clinical immunology. In practice · 2026
    Article
  4. Direct oral challenges safely reduce the burden of low-risk cephalosporin allergy labels.The journal of allergy and clinical immunology. In practice · 2025
    Article
  5. Evaluation of cephalosporin allergy: Survey of drug allergy experts.The journal of allergy and clinical immunology. Global · 2025
    Article
  6. Article
  7. Article
  8. Cephalosporin Allergy: Updates on Diagnostic Testing.Current allergy and asthma reports · 2024
    Review
  9. A call to address penicillin allergy labels in patients with hematopoietic stem cell transplants: How to avoid rash decisions.Transplant infectious disease : an official journal of the Transplantation Society · 2024
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Grace KooDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
Roger YuUniversity of Chicago Pritzker School of Medicine, Chicago, Ill.
Elizabeth J PhillipsDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tenn; Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, WA, Australia.
Cosby A StoneDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn. Electronic address: cosby.a.stone@vumc.org.

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisU01AI154659 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2020 to 2025
$15.5M
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1M
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)R01AI152183 · NIAID · UNIVERSITY OF CAPE TOWN · PI MEINTJES, GRAEME AYTON, PHILLIPS, ELIZABETH · 2020 to 2025
$1.6M
Stevens-Johnson syndrome/toxic epidermal necrolysis 2021: Collaboration, Innovation and CommunityR13AR078623 · NIAMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2021 to 2021
$33k
AHRQ HHS K12 HS026395NHGRI NIH HHS R01 HG010863NIAID NIH HHS R01 AI152183NIAID NIH HHS U01 AI154659NIAMS NIH HHS R13 AR078623
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug HypersensitivityPenicillinsAnti-Bacterial AgentsCephalosporinsHumansRetrospective StudiesAnti-Bacterial AgentsCephalosporinsPenicillins

Identifiers

PMID35690369
PMCPMC13126447

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.